Stock analysts at HC Wainwright issued their FY2024 earnings estimates for Immunic in a report issued on Monday, November ...

Gain Therapeutics, Inc. (NASDAQ:GANX – Free Report) – Research analysts at HC Wainwright lifted their FY2024 EPS estimates ...

Fintel reports that on November 26, 2024, HC Wainwright & Co. downgraded their outlook for Cassava Sciences (NasdaqCM:SAVA) ...

Fintel reports that on November 25, 2024, HC Wainwright & Co. downgraded their outlook for Mainz Biomed N.V. (NasdaqCM:MYNZ) ...

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of SoundHound AI ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

To access the live webcast of the fireside chat, please visit: https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available on the Arbutus website for a ...

H.C. Wainwright analyst Matthew Caufield initiated coverage of Immunic (IMUX) with a Buy rating and $10 price target The firm likes the company’s “comprehensive” neuroprotective and anti ...

After Amgen (AMGN) announced topline data from its Phase 2 study of MariTide, the company’s subcutaneously administered GLP-1 weight loss drug, H.C. Wainwright contends that Viking Therapeutics ...

On Tuesday, H.C. Wainwright maintained a Neutral rating for Mawson Infrastructure Group Inc. (NASDAQ: MIGI), following the company's recent production report. Mawson Infrastructure, transitioning from ...

On Tuesday, H.C. Wainwright maintained a Neutral rating for Mawson Infrastructure Group Inc. (NASDAQ: MIGI), following the company's recent production report. Mawson Infrastructure, transitioning ...